



MEDIPOLIS GMP

Free to be published

10.6.05

PRESS RELEASE

Medipolis GMP is announcing about cooperation agreement with Scil Proteins GmbH and manufacturing contract with Evolutec Plc., an UK based biotech company.

Medipolis GMP Ltd. is a Finnish small scale contract manufacturer of biologics. The company is owned by a Finnish venture capitalist Teknoventure Ltd. and the management team. The company is specialized in offering microbial fermentation for drug development companies.

Medipolis GMP has entered into cooperation agreement with German Scil Proteins GmbH. Scil Proteins is specialized in process development of microbial production systems, but does not have GMP facilities. Medipolis GMP Ltd has both CMP clean room facilities and strong industrial and regulatory experience. The cooperation agreement covers technology and business development and joint efforts in sales and marketing. Companies can offer integrated services and better serve their customers. The first joint activity will be in June 19.-22. Bio05 in Philadelphia, USA. Bio05 is arranged annually and it is the largest and most important bio business gathering in the world.

Medipolis GMP Ltd. Has also entered into manufacturing contract with Evolutec plc. an UK based biotech company about production of clinical material. The project is an important opening to the international market.

Medipolis GMP has revised its strategy and actively invested on international business development and sales and marketing. The overall improvement of funding situation has lead to increased demand for services.

For more information:

Pirkko Suhonen, CEO +358-44-521 2688, e-mail
pirkko.suhonen@medipolisgmp.com

Tuulikki Marjomaa, Chair of the board +358 -40-775 7317 e-mail
tuulikki.marjomaa@teknoventure.fi

MEDIPOLIS GMP LTD

Kiviharjuntie 11, 90220 Oulu, Finland

Tel. +358(0)207 545 880 , Fax. +358 (0)207 545 879